Cargando…

Corrigendum to “Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes”

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047821/ https://www.ncbi.nlm.nih.gov/pubmed/33912329 http://dx.doi.org/10.1177/20406223211002790

Ejemplares similares

Drug-induced liver injury after switching from tamoxifen to anastrozole in a patient with a history of breast cancer being treated for hypertension and diabetes
por: Potmešil, Petr, et al.
Publicado: (2020)

Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors
por: Eisner, Alvin, et al.
Publicado: (2007)

A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer
por: Lin, Ying, et al.
Publicado: (2014)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
por: Kemp, Anna, et al.
Publicado: (2014)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
por: Li, Jian-wei, et al.
Publicado: (2018)

A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer
por: Yang, Yan, et al.
Publicado: (2017)

Escitalopram co-prescription in anastrozole-treated breast cancer patients
por: Ozyurt, Hazan, et al.
Publicado: (2022)

Correlation Between Anthropometric Measures and Biomarker Changes After Neoadjuvant Therapy With Tamoxifen or Anastrozole in Postmenopausal Women With Breast Cancer
por: Cintra, Karine A., et al.
Publicado: (2010)

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
por: GHIMENTI, CHIARA, et al.
Publicado: (2013)

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)

Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy
por: Aphinives, Potchavit, et al.
Publicado: (2014)

Effects of cyclin D(1 )gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
por: Lundgren, Katja, et al.
Publicado: (2012)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial
por: Mansel, R, et al.
Publicado: (2007)

Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells
por: Hassan, Firas, et al.
Publicado: (2017)

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Effects of psoralen on the pharmacokinetics of anastrozole in rats
por: Zhang, Yuzhu, et al.
Publicado: (2018)

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
por: Aphinives, Potchavit, et al.
Publicado: (2015)

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
por: Bojanić, Kristina, et al.
Publicado: (2018)

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: Results of the JMTO BC08-01 phase II trial
por: NISHIMURA, REIKI, et al.
Publicado: (2013)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001)

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
por: Madeira, Marcelo, et al.
Publicado: (2013)

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
por: Forbes, John F, et al.
Publicado: (2016)

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events
por: Kim, Yoo Jung, et al.
Publicado: (2020)

Biophysical Insight into the Interaction of Human Lysozyme with Anticancer Drug Anastrozole: A Multitechnique Approach
por: Almutairi, Fahad M., et al.
Publicado: (2020)

Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole
por: Tugce Yesil, Devecioglu, et al.
Publicado: (2018)

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment
por: Campbell, Aideen M, et al.
Publicado: (2018)

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005)

Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation
por: Regenthal, Ralf, et al.
Publicado: (2018)

Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole
por: Gorski, Justin Wayne, et al.
Publicado: (2017)

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
por: Ximenez, João Paulo Bianchi, et al.
Publicado: (2019)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]
Publicado: (2022)

Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer
por: Anderson, T J, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_cdtiqgfap2p8o5gs3f87m9uvme